ArticleResearch square2025
Molecular Profiling of Primary versus Paired Asynchronous Metastatic Clear Cell Renal Cell Carcinoma Reveals Heterogeneity in Tumor Immune Microenvironment.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
16 authors.
Funding
Abstract
Background and Objective: The tumor immune microenvironment (TIME) shows significant heterogeneity in primary clear cell renal cell carcinoma (ccRCC). As TIME heterogeneity between primary and paired metastatic tumors of ccRCC is less understood, we characterize and compare the TIME of primary ccRCC with paired asynchronous metastases. Methods: We analyzed patients who developed ccRCC recurrence post radical nephrectomy and had both primary and metastatic treatment-naïve tissue available. Capture whole-transcriptome sequencing was performed on formalin-fixed paraffin-embedded (FFPE) specimens using the Illumina platform. Differential gene expression (DGE) analysis and gene set enrichment analysis (GSE) was performed using R packages limma and fgsea respectively. TIME deconvolution was quantified using CIBERSORT, an Key Findings and Limitations: In aggregate, 42 tumor samples from 19 patients (19 primary tumors with 23 matched metastases) were analyzed. Metastatic sites included lung (n = 6), bone (n = 6), adrenal (n = 4), liver (n = 2), lymph node (n = 2), and soft tissue (n = 3). In unsupervised hierarchical clustering, primary tumors clustered together and not with their matched metastatic tumor. Of the immune cells assayed, primary tumors displayed greater Tregs than their matched (and unmatched) metastases (p < 0.001). Among metastatic sites, bone had high levels of EMT activity compared to their matched primary tumors and lung metastatic tumors were enriched in E2F targets. Conclusions and Clinical Implications: We demonstrate differences in pathway enrichment and immune cell populations in primary ccRCC and their matched metastases, including a higher infiltration of immunosuppressive T regulatory cells in the tumor immune microenvironment of primary renal ccRCC. Metastatic tumors not only differed from their paired primary tumors but also differed in gene expression, gene set enrichment, and immune cell composition between metastatic tissue sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.